Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Friday, September 21, 2018 · 462,588,744 Articles · 3+ Million Readers

Detailed Research: Economic Perspectives on Omega Healthcare Investors, Vanda Pharmaceuticals, Acushnet, Prospect Capital, Intercontinental Exchange, and Glaukos — What Drives Growth in Today's Competitive Landscape

NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Omega Healthcare Investors, Inc. (NYSE:OHI), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Acushnet Holdings Corp. (NYSE:GOLF), Prospect Capital Corporation (NASDAQ:PSEC), Intercontinental Exchange Inc. (NYSE:ICE), and Glaukos Corporation (NYSE:GKOS), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

/EIN News/ -- Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

OHI DOWNLOAD: http://Fundamental-Markets.com/register/?so=OHI
VNDA DOWNLOAD: http://Fundamental-Markets.com/register/?so=VNDA
GOLF DOWNLOAD: http://Fundamental-Markets.com/register/?so=GOLF
PSEC DOWNLOAD: http://Fundamental-Markets.com/register/?so=PSEC
ICE DOWNLOAD: http://Fundamental-Markets.com/register/?so=ICE
GKOS DOWNLOAD: http://Fundamental-Markets.com/register/?so=GKOS

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Omega Healthcare Investors, Inc. (NYSE:OHI), Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), Acushnet Holdings Corp. (NYSE:GOLF), Prospect Capital Corporation (NASDAQ:PSEC), Intercontinental Exchange Inc. (NYSE:ICE), and Glaukos Corporation (NYSE:GKOS) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed February 9th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

OMEGA HEALTHCARE INVESTORS, INC. (OHI) REPORT OVERVIEW

Omega Healthcare Investors' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Omega Healthcare Investors reported revenue of $219.64MM vs $224.64MM (down 2.23%) and basic earnings per share -$0.67 vs $0.40. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Omega Healthcare Investors reported revenue of $900.83MM vs $743.62MM (up 21.14%) and basic earnings per share $1.91 vs $1.30 (up 46.92%). Omega Healthcare Investors is expected to report earnings on February 13th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.88. The estimated EPS forecast for the next fiscal year is $3.23 and is expected to report on February 13th, 2018.

To read the full Omega Healthcare Investors, Inc. (OHI) report, download it here: http://Fundamental-Markets.com/register/?so=OHI

-----------------------------------------

VANDA PHARMACEUTICALS INC. (VNDA) REPORT OVERVIEW

Vanda Pharmaceuticals' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Vanda Pharmaceuticals reported revenue of $41.34MM vs $38.48MM (up 7.42%) and basic earnings per share -$0.10 vs -$0.01. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Vanda Pharmaceuticals reported revenue of $146.02MM vs $109.93MM (up 32.83%) and basic earnings per share -$0.41 vs -$0.94. Vanda Pharmaceuticals is expected to report earnings on February 14th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal year is -$0.30 and is expected to report on February 14th, 2018.

To read the full Vanda Pharmaceuticals Inc. (VNDA) report, download it here: http://Fundamental-Markets.com/register/?so=VNDA

-----------------------------------------

ACUSHNET HOLDINGS CORP. (GOLF) REPORT OVERVIEW

Acushnet's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Acushnet reported revenue of $347.26MM vs $339.32MM (up 2.34%) and basic earnings per share $0.13 vs -$0.38. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Acushnet reported revenue of $1,572.28MM vs $1,502.96MM (up 4.61%) and basic earnings per share $0.74 vs -$0.74. Acushnet is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is $1.37 and is expected to report on March 29th, 2018.

To read the full Acushnet Holdings Corp. (GOLF) report, download it here: http://Fundamental-Markets.com/register/?so=GOLF

-----------------------------------------

PROSPECT CAPITAL CORPORATION (PSEC) REPORT OVERVIEW

Prospect Capital's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Prospect Capital reported revenue of $162.40MM vs $183.48MM (down 11.49%) and basic earnings per share $0.34 vs $0.28 (up 21.43%). For the twelve months ended June 30th, 2017 vs June 30th, 2016, Prospect Capital reported revenue of $701.05MM vs $791.97MM (down 11.48%) and basic earnings per share $0.70 vs $0.29 (up 141.38%). Prospect Capital is expected to report earnings on May 8th, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.20. The estimated EPS forecast for the next fiscal year is $0.73 and is expected to report on August 27th, 2018.

To read the full Prospect Capital Corporation (PSEC) report, download it here: http://Fundamental-Markets.com/register/?so=PSEC

-----------------------------------------

INTERCONTINENTAL EXCHANGE INC. (ICE) REPORT OVERVIEW

Intercontinental Exchange's Recent Financial Performance

For the three months ended December 31st, 2017 vs December 31st, 2016, Intercontinental Exchange reported revenue of $1,144.00MM vs $1,138.00MM (up 0.53%) and basic earnings per share $2.09 vs $0.59 (up 254.24%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Intercontinental Exchange reported revenue of $4,629.00MM vs $4,499.00MM (up 2.89%) and basic earnings per share $4.27 vs $2.39 (up 78.66%). Intercontinental Exchange is expected to report earnings on May 2nd, 2018. The report will be for the fiscal period ending March 31st, 2018. The reported EPS for the same quarter last year was $0.74. The estimated EPS forecast for the next fiscal year is $3.88 and is expected to report on February 6th, 2019.

To read the full Intercontinental Exchange Inc. (ICE) report, download it here: http://Fundamental-Markets.com/register/?so=ICE

-----------------------------------------

GLAUKOS CORPORATION (GKOS) REPORT OVERVIEW

Glaukos' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Glaukos reported revenue of $40.41MM vs $29.58MM (up 36.63%) and basic earnings per share $0.04 vs $0.03 (up 33.33%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Glaukos reported revenue of $114.40MM vs $71.70MM (up 59.55%) and basic earnings per share $0.14 vs -$2.13. Glaukos is expected to report earnings on February 28th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.00. The estimated EPS forecast for the next fiscal year is $0.03 and is expected to report on February 28th, 2018.

To read the full Glaukos Corporation (GKOS) report, download it here: http://Fundamental-Markets.com/register/?so=GKOS

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.


Powered by EIN News